LORBRENA
Identification of Lorbrena
| No description |
Google image searchProduct monograph
Active ingredient
lorlatinib, 25 MG
DIN: 02485966
Dosage form(s): TABLET
Route(s) of administration: ORAL
Schedule: Prescription
Company: PFIZER CANADA ULC
Date: 22-APR-2019
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01E — PROTEIN KINASE INHIBITORS (ATC, ATC/DDD)
- L01ED — Anaplastic lymphoma kinase (ALK) inhibitors (ATC, ATC/DDD)
- L01ED05 — LORLATINIB (ATC/DDD)
